ibrutinib,venetoclax,rituximab
roche,janssen,abbvie,biogen
[]
great talk from #petehillmen . flair: large ph3 adaptive trial design - data at #eha 2022 reporting the interim ep for the i+v vs i-mono comparison. importantly - duration of therapy informed by individual patient time-to-mrd data 
Professor of Haematology & Consultant Haematologist, University of Nottingham & N.U.H, UK.  Chair, NCRI high-grade lymphoma group. (no med advice)